Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
93 hedge funds and large institutions have $317M invested in Adamas Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 15 closing their positions.
699% more call options, than puts
Call options by funds: $831K | Put options by funds: $104K
80% more capital invested
Capital invested by funds: $176M → $317M (+$141M)
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
12% more funds holding
Funds holding: 83 → 93 (+10)
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.51M |
| 2 |
Millennium Management
New York
|
+$5.38M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.89M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.86M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPH
C Partners Holding
Zurich,
Switzerland
|
-$8M |
| 2 |
BS
Bow Street
New York
|
-$2.54M |
| 3 |
Renaissance Technologies
New York
|
-$2.38M |
| 4 |
WSA
Wall Street Associates
Lajolla,
California
|
-$1.68M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.66M |
ADMS Hedge Fund Activity: Q4 2015 in Review
93 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2015, worth a combined $317M — up 80% from $176M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ADMS positions and 15 closed out — a net gain of 10 holders — while 28 added to existing stakes and 25 trimmed.
The largest buyer was Great Point Partners, adding an estimated $5.51M. The largest seller was C Partners Holding, cutting an estimated $8M.
- 93 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2015, up from 83 in Q3 2015.
- Funds reported $317M of Adamas Pharmaceuticals stock for Q4 2015, up 80% quarter-over-quarter.
- 25 funds opened new Adamas Pharmaceuticals positions in Q4 2015 and 15 closed out, a net change of +10 holders.
- The largest Adamas Pharmaceuticals buyer in Q4 2015 was Great Point Partners, an estimated $5.51M added.
- The largest Adamas Pharmaceuticals seller in Q4 2015 was C Partners Holding, an estimated $8M sold.
Based on aggregated 13F filings for Q4 2015.